Phosphate binding therapy to lower serum fibroblast-growth-factor-23 concentrations in chronic kidney disease: rationale and study design of the Sevelamer on …
AY Adema, MA de Jong, MH de Borst, PM Ter Wee… - Nephron, 2016 - karger.com
Background: Increased levels of phosphate and fibroblast growth factor-23 (FGF23) are
strong predictors of cardiovascular morbidity and mortality in patients with chronic kidney …
strong predictors of cardiovascular morbidity and mortality in patients with chronic kidney …
[PDF][PDF] Phosphate Binding Therapy to Lower Serum Fibroblast-Growth-Factor-23 Concentrations in Chronic Kidney Disease: Rationale and Study Design of the …
AY Adema, MA de Jong, MH de Borst, PM ter Wee - Nephron, 2016 - core.ac.uk
Background: Increased levels of phosphate and fibroblast growth factor-23 (FGF23) are
strong predictors of cardiovascular morbidity and mortality in patients with chronic kidney …
strong predictors of cardiovascular morbidity and mortality in patients with chronic kidney …
Phosphate Binding Therapy to Lower Serum Fibroblast-Growth-Factor-23 Concentrations in Chronic Kidney Disease: Rationale and Study Design of the Sevelamer …
AY Adema, MA de Jong, MH de Borst, PM Ter Wee… - Nephron, 2016 - europepmc.org
Background Increased levels of phosphate and fibroblast growth factor-23 (FGF23) are
strong predictors of cardiovascular morbidity and mortality in patients with chronic kidney …
strong predictors of cardiovascular morbidity and mortality in patients with chronic kidney …
Phosphate Binding Therapy to Lower Serum Fibroblast-Growth-Factor-23 Concentrations in Chronic Kidney Disease: Rationale and Study Design of the Sevelamer …
AY Adema, MA de Jong, MH de Borst… - …, 2016 - pubmed.ncbi.nlm.nih.gov
Background Increased levels of phosphate and fibroblast growth factor-23 (FGF23) are
strong predictors of cardiovascular morbidity and mortality in patients with chronic kidney …
strong predictors of cardiovascular morbidity and mortality in patients with chronic kidney …
[HTML][HTML] Phosphate Binding Therapy to Lower Serum Fibroblast-Growth-Factor-23 Concentrations in Chronic Kidney Disease: Rationale and Study Design of the …
AY Adema, MA de Jong, MH de Borst… - Nephron. Clinical …, 2016 - ncbi.nlm.nih.gov
Background Increased levels of phosphate and fibroblast growth factor-23 (FGF23) are
strong predictors of cardiovascular morbidity and mortality in patients with chronic kidney …
strong predictors of cardiovascular morbidity and mortality in patients with chronic kidney …
[HTML][HTML] Phosphate Binding Therapy to Lower Serum Fibroblast-Growth-Factor-23 Concentrations in Chronic Kidney Disease: Rationale and Study Design of the …
AY Adema, MA de Jong, MH de Borst, PM ter Wee… - Nephron, 2016 - karger.com
Background: Increased levels of phosphate and fibroblast growth factor-23 (FGF23) are
strong predictors of cardiovascular morbidity and mortality in patients with chronic kidney …
strong predictors of cardiovascular morbidity and mortality in patients with chronic kidney …
Phosphate Binding Therapy to Lower Serum Fibroblast-Growth-Factor-23 Concentrations in Chronic Kidney Disease: Rationale and Study Design of the Sevelamer …
AY Adema, MA de Jong, MH de Borst, PM Ter Wee… - Nephron, 2016 - research.rug.nl
Background: Increased levels of phosphate and fibroblast growth factor-23 (FGF23) are
strong predictors of cardiovascular morbidity and mortality in patients with chronic kidney …
strong predictors of cardiovascular morbidity and mortality in patients with chronic kidney …
[引用][C] Phosphate Binding Therapy to Lower Serum Fibroblast-Growth-Factor-23 Concentrations in Chronic Kidney Disease: Rationale and Study Design of the …
AY Adema, MA de Jong, MH de Borst… - …, 2016 - researchinformation.amsterdamumc …
Phosphate Binding Therapy to Lower Serum Fibroblast-Growth-Factor-23 Concentrations in
Chronic Kidney Disease: Rationale and Study Design of the Sevelamer on FGF23 Trial (SoFT) …
Chronic Kidney Disease: Rationale and Study Design of the Sevelamer on FGF23 Trial (SoFT) …
[PDF][PDF] VU Research Portal
AY Adema - PLOS ONE, 2016 - research.vu.nl
The CKD-associated decline in soluble α-Klotho levels is considered detrimental. Some in
vitro and in vivo animal studies have shown that anti-oxidant therapy can upregulate the …
vitro and in vivo animal studies have shown that anti-oxidant therapy can upregulate the …
Phosphate Binding Therapy to Lower Serum Fibroblast-Growth-Factor-23 Concentrations in Chronic Kidney Disease: Rationale and Study Design of the Sevelamer …
AY Adema, MA de Jong, MH de Borst, PM Ter Wee… - Nephron, 2016 - europepmc.org
Background Increased levels of phosphate and fibroblast growth factor-23 (FGF23) are
strong predictors of cardiovascular morbidity and mortality in patients with chronic kidney …
strong predictors of cardiovascular morbidity and mortality in patients with chronic kidney …